Study Details
Design, interventions, and primary outcomes
About This Study
This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 trial participants are expected to be enrolled, with trial participants randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.
Design
Interventions / Regimen
- Drug: TQC2731 injection — TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
- Drug: Placebo — Placebo without drug substance.
Primary Outcomes
- Annualized incidence of asthma exacerbations (From the first day of dosing to the completion of 52 weeks of treatment)
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-21
Completion: 2028-03
Sex: ALL
Volunteers: false
Enrollment: 660 (ESTIMATED)
- Drug: TQC2731 injection — TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
- Drug: Placebo — Placebo without drug substance.